Category: CDE

Categories
CDE Diabetes

Practice Exam: Neuropathy (Chapter 31)

Diabetic neuropathy is the most common complication of diabetes in North America, often developing within 10 years of diagnosis in up to 50% of patients. The 2018 Clinical Practice Guidelines stress that while there is no cure, the progression of neuropathy can be significantly delayed with early detection and optimal glycemic control.

This practice exam tests your ability to apply screening protocols, differentiate between peripheral and autonomic neuropathies, and select appropriate pharmacologic treatments for neuropathic pain.

Key Concepts Covered in This Exam:

  • Screening Protocols: Mastering the different screening timelines for Type 1 diabetes (starting 5 years post-diagnosis) versus Type 2 diabetes (at diagnosis) and the use of the 10 g monofilament or 128 Hz tuning fork.
  • Prevention Strategies: Understanding that intensive glycemic control is effective for preventing neuropathy in Type 1 diabetes and reducing its frequency in Type 2 diabetes.
  • Pain Management: Identifying evidence-based pharmacotherapies for painful diabetic neuropathy, including anticonvulsants (pregabalin, gabapentin) and antidepressants (duloxetine, venlafaxine), while recognizing that opioids are second-line or last-resort agents.
  • Autonomic Neuropathy: Recognizing the signs of cardiac autonomic neuropathy (CAN), gastroparesis, and erectile dysfunction, and the risks associated with them, such as resting tachycardia and postural hypotension.
  • Diagnostic Limitations: Knowing that simple screening tests like the monofilament are excellent for identification but that diagnosis requires excluding other causes (e.g., B12 deficiency, alcohol use).

1. A 45-year-old patient is newly diagnosed with type 2 diabetes. When should screening for peripheral neuropathy be initiated?

2. A diabetes educator is counseling a patient about why underdiagnosis of neuropathy is a problem. According to the guideline, which statement best summarizes the clinical impact of underdiagnosis?

3. According to the guideline, what is the relationship between neuropathy and prediabetes?

4. A 55-year-old with type 1 diabetes for 25 years has painful neuropathy and symptoms of orthostatic hypotension. You want to initiate duloxetine for pain management. What additional consideration is important regarding orthostatic hypotension treatment?

5. Diabetes is the leading cause of neuropathy in which geographic region?

6. A patient with severe gastroparesis requires temporary pharmacologic treatment with a prokinetic agent. Which medication may be used, but with limited duration due to risk of extrapyramidal side effects?

7. A patient with type 2 diabetes presents with unilateral facial weakness. Which cranial nerves are most commonly affected in diabetic cranial neuropathies?

8. What percentage of people with type 1 or type 2 diabetes will develop detectable sensorimotor polyneuropathy within 10 years of diabetes onset?

9. A patient with type 2 diabetes and peripheral neuropathy has been found to have abnormal heart rate variability testing. Why is this finding clinically significant?

10. A patient with type 2 diabetes on metformin presents with new peripheral neuropathy symptoms. Which investigation is particularly important given the medication history?

11. When performing monofilament screening for diabetic neuropathy, where should the 10 g monofilament be applied?

12. A patient with diabetic gastroparesis is currently on a GLP-1 receptor agonist. What is the recommended approach regarding this medication?

13. Conservative measures for postural hypotension management include all of the following EXCEPT:

14. When treating painful diabetic neuropathy, what degree of pain reduction is considered a clinically meaningful response?

15. Which of the following is the most common form of diabetic neuropathy?

16. What defines postural hypotension in the diagnosis of cardiac autonomic neuropathy?

17. A patient with painful diabetic neuropathy asks about treatment options. Which medications have received Health Canada approval specifically for neuropathic pain in diabetes?

18. Which two screening tools are recommended for rapid, reliable asymptomatic screening for peripheral neuropathy?

19. What resting heart rate is considered a feature of cardiac autonomic neuropathy (resting tachycardia)?

20. Which type of neuropathy can be distinguished from polyneuropathy by electrophysiological studies and is common in diabetes?

21. Why is the primary use of opioids NOT recommended as first-line therapy for painful diabetic neuropathy, despite clinical trial evidence for pain efficacy?

22. Which of the following is NOT a recognized risk factor for diabetic neuropathy?

23. Bladder dysfunction in diabetic autonomic neuropathy can include all of the following EXCEPT:

24. A 48-year-old patient with newly diagnosed type 2 diabetes presents with bilateral burning pain in both feet. Physical examination and nerve conduction studies are normal. Which statement best explains this presentation?

25. A 22-year-old patient was diagnosed with type 1 diabetes at age 14 (post-pubertal). When should annual screening for neuropathy have commenced or should commence?

26. A patient with type 2 diabetes has symptoms of asymmetric neuropathy with greater motor than sensory impairment. What is the recommended approach?

27. What is the suggested starting dose for pregabalin in the treatment of painful diabetic neuropathy?

28. The most common early symptoms of diabetic neuropathy from small fibre involvement include:

29. According to the DCCT/EDIC study, what is the prevalence of cardiac autonomic neuropathy (CAN) after 20 years of type 1 diabetes?

30. A patient presents with excessive sweating in the head and neck triggered by food consumption. What type of diabetic autonomic neuropathy manifestation does this represent?

31. What is the maximum tolerated dose of gabapentin for painful diabetic neuropathy?

32. A patient asks about surgical release of distal lower limb nerves for diabetic neuropathy. What is the recommendation?

33. Based on the DCCT and its follow-up studies, for how long do the benefits of intensive insulin treatment persist for the primary prevention of neuropathy in type 1 diabetes?

34. A patient with diabetes and diabetic bladder dysfunction needs treatment for painful neuropathy. Which medication is contraindicated in this patient?

35. For treatment of postural hypotension in diabetic autonomic neuropathy, which of the following is a specific pharmacologic therapy?

36. Regarding the use of capsaicin cream for painful diabetic neuropathy, what limits its acceptability and generalizability in clinical practice?

37. What is the prevalence of erectile dysfunction in men with diabetic autonomic neuropathy?

38. How does the 10 g monofilament test for annual DSPN screening differ from testing to assess risk for foot ulceration?


 

Categories
CDE Diabetes

Study Guide: Neuropathy (Chapter 31)

1. Overview & Pathophysiology

Diabetic neuropathy is a heterogeneous group of disorders affecting the somatic and autonomic nervous systems. It is the most common complication of diabetes.

  • Distal Symmetric Polyneuropathy (DSPN): The most common form, typically presenting as a “stocking-glove” sensory loss or pain. It is a major risk factor for foot ulcers and amputation.

  • Risk Factors: The development of neuropathy is multifactorial. Key risk factors include:

    • Elevated blood glucose (A1C).

    • Elevated triglycerides.

    • High Body Mass Index (BMI).

    • Smoking.

    • Hypertension.

2. Screening Protocols

Screening is vital because the early stages of neuropathy are often asymptomatic (loss of sensation).

  • Frequency:

    • Type 1 Diabetes: Start 5 years post-diagnosis, then annually.

    • Type 2 Diabetes: Start at diagnosis, then annually.

  • Method (The “10g Monofilament”):

    • Screening should include testing with a 10g Semmes-Weinstein monofilament to detect Loss of Protective Sensation (LOPS).

    • Other assessments:

      • Vibration (128 Hz tuning fork).

      • Temperature.

      • Pinprick sensation.

      • Proprioception.

3. Management Strategies

Management is divided into prevention/slowing progression and symptom management.

A. Disease Modification (Glycemic Control)

  • Type 1 Diabetes: Intensive glycemic control significantly prevents or delays the development of neuropathy.

  • Type 2 Diabetes: Intensive control reduces the frequency of neuropathy but is less effective than in Type 1.

B. Management of Painful Neuropathy Neuropathic pain can be severe and debilitating (burning, shooting, lancinating). Treatment aims to reduce pain by ~30–50% and improve quality of life/sleep.

  • First-Line Pharmacotherapy:

    • Anticonvulsants: Pregabalin, Gabapentin.

    • Antidepressants (SNRI): Duloxetine, Venlafaxine.

    • Antidepressants (TCA): Amitriptyline, Nortriptyline (use with caution due to anticholinergic side effects).

  • Second-Line:

    • Opioid-like agents (e.g., Tramadol, Tapentadol) may be considered but have higher risk profiles.

5. Diabetes Canada 2018 Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S220).

  1. Screening:

    • Type 1: Screen annually starting 5 years post-diagnosis [Grade D, Consensus].

    • Type 2: Screen annually starting at diagnosis [Grade D, Consensus].

  2. Tools: Use the 10g monofilament testing of the dorsal aspect of the great toe.

  3. Glycemic Control: Optimize control to prevent/delay neuropathy in Type 1 [Grade A, Level 1] and Type 2 [Grade B, Level 2].

  4. Pain Management:

    • Examples of agents: Pregabalin, Duloxetine, Gabapentin, Amitriptyline, Venlafaxine [Grade B, Level 2 for most].

    • Opioids (Tapentadol, Tramadol) are second-line [Grade B].

Reference:

Bril V, Breiner A, Perkins BA, Zochodne D. Neuropathy. Canadian Journal of Diabetes. 2018;42:S217-S221. doi:10.1016/j.jcjd.2017.10.028
Categories
CDE Diabetes

Flashcards: Retinopathy (Chapter 30)

Diabetic retinopathy remains the leading cause of new cases of blindness in working-age adults. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding screening intervals, the “ABC” prevention strategy, and the shift toward newer pharmacological treatments for preserving vision.

Key Topics Covered:

  • Screening Schedules: Memorizing the distinct initiation times for Type 1 diabetes (5 years post-diagnosis) versus Type 2 diabetes (at diagnosis) and follow-up frequencies.

  • Therapeutic Interventions: Identifying anti-VEGF (vascular endothelial growth factor) therapy as the first-line treatment for center-involved diabetic macular edema (DME).

  • The “ABCs” of Prevention: Recalling the role of optimal A1C, Blood pressure, and Cholesterol control—specifically the use of fenofibrate—in slowing disease progression.

  • Pregnancy Risks: Understanding why pregnancy confers a high risk for rapid retinopathy progression and the need for first-trimester screening.

  • Referral Criteria: Knowing when to refer to an ophthalmologist versus when optometric screening is sufficient.

Categories
CDE Diabetes

Practice Exam: Retinopathy (Chapter 30)

Diabetic retinopathy remains the leading cause of new cases of blindness in adults of working age. The 2018 Clinical Practice Guidelines emphasize that with optimal glycemic and blood pressure control, coupled with regular screening and timely treatment, the vast majority of vision loss can be prevented.

This practice exam tests your ability to apply specific screening schedules, recognize the risk factors for progression, and identify the appropriate therapeutic interventions for sight-threatening disease.

Key Concepts Covered in This Exam:

  • Screening Protocols: Mastering the different screening initiation times for Type 1 diabetes (5 years after diagnosis) versus Type 2 diabetes (at diagnosis) and the frequency of follow-up.

  • Risk Reduction: Understanding the evidence behind “ABC” management (A1C, Blood pressure, Cholesterol) and the specific role of fenofibrate in slowing retinopathy progression.

  • Therapeutic Interventions: Identifying anti-VEGF (vascular endothelial growth factor) therapy as the first-line treatment for center-involved diabetic macular edema (DME), replacing standard laser therapy for many patients.

  • Pregnancy Considerations: Recognizing the rapid progression of retinopathy that can occur during pregnancy and the requirement for more frequent ophthalmological assessments.

  • Referral Pathways: Knowing when to refer patients to an optometrist or ophthalmologist and how to interpret screening results to determine follow-up intervals.

Please go to Practice Exam: Retinopathy (Chapter 30) to view this quiz

Categories
CDE Diabetes

Study Guide: Retinopathy (Chapter 30)

1. Overview & Epidemiology

Diabetic Retinopathy (DR) is the leading cause of new cases of blindness in adults aged 20–65 years in North America.

  • Risk Factors: The development and progression of DR are primarily driven by:

    • Duration of diabetes: The strongest predictor.

    • Glycemic control (A1C): Better control reduces risk.

    • Hypertension: Elevated BP accelerates progression.

    • Dyslipidemia: Associated with hard exudates and vision loss.

2. Pathophysiology & Classification

DR progresses through distinct stages, characterized by damage to the small blood vessels in the retina.

  • Non-Proliferative Diabetic Retinopathy (NPDR):

    • Early: Microaneurysms (outpouching of capillaries).

    • Moderate/Severe: Intraretinal hemorrhages, hard exudates (lipid deposits), cotton wool spots (nerve fiber infarction), and venous beading.

    • Key Feature: Absence of new blood vessels.

  • Proliferative Diabetic Retinopathy (PDR):

    • Key Feature: Neovascularization (growth of new, fragile blood vessels) on the retina or optic disc.

    • Risk: These vessels bleed easily (vitreous hemorrhage) and cause fibrosis, leading to tractional retinal detachment and severe vision loss.

  • Diabetic Macular Edema (DME):

    • Fluid leakage/swelling in the macula (the center of vision).

    • Can occur at ANY stage (NPDR or PDR) and is the most common cause of visual impairment in people with diabetes.

3. Screening Recommendations

Screening allows for early detection and treatment to prevent blindness. Visual acuity testing alone is insufficient; a comprehensive dilated eye exam is required.

A. Type 1 Diabetes

  • Start: 5 years after diagnosis (usually not before puberty).

  • Frequency: Annually.

B. Type 2 Diabetes

  • Start: At diagnosis.

  • Frequency: Every 1–2 years. (Interval can be extended to 2 years if there is no retinopathy and glycemic control is stable).

C. Pregnancy (Type 1 or Type 2)

  • Planning: Screen prior to conception.

  • During Pregnancy: Screen in the first trimester.

  • Follow-up: As determined by the eye specialist (DR can progress rapidly during pregnancy).

  • Note: This does not apply to Gestational Diabetes (GDM), as they are not at increased risk for DR during pregnancy.

4. Prevention & Management

Primary prevention focuses on systemic factors, while secondary treatment targets the eye directly.

Systemic Management (The “ABC”s):

  • A1C: Optimal glycemic control slows the onset and progression of retinopathy.

  • Blood Pressure: Control (<130/80 mmHg) is critical.

  • Cholesterol: Fenofibrate has been shown to slow progression of retinopathy (FIELD and ACCORD-Eye trials), particularly in those with mild-to-moderate NPDR, independent of lipid levels.

Ocular Treatment Options:

  1. Laser Photocoagulation:

    • Pan-Retinal Photocoagulation (PRP): Used for PDR. Burns the peripheral retina to stop neovascularization.

    • Focal/Grid Laser: Used for DME (historically the standard, now often second-line).

  2. Intraocular Pharmacotherapy (Injections):

    • Anti-VEGF Agents (e.g., ranibizumab, aflibercept, bevacizumab): Now first-line therapy for center-involving DME with vision loss. They reduce fluid and improve vision.

    • Steroids: For resistant cases.

  3. Vitrectomy: Surgery to remove blood (vitreous hemorrhage) or scar tissue (retinal detachment).

5. Diabetes Canada 2018 Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S215).

  1. Screening Intervals:

    • Type 1: Start 5 years after diagnosis, then annually [Grade A, Level 1].

    • Type 2: Start at diagnosis, then every 1–2 years [Grade A, Level 1].

  2. Screening Method: Assessments should be performed by an experienced professional (optometrist/ophthalmologist) through dilated pupils [Grade D, Consensus].

  3. Pregnancy: Screen women with T1D or T2D pre-conception, in the first trimester, and as needed thereafter [Grade D, Consensus].

  4. DME Treatment: Intraocular anti-VEGF therapy is recommended as first-line for center-involving diabetic macular edema with vision loss [Grade A, Level 1].

  5. Fenofibrate: Fenofibrate (in addition to statins) may be used in patients with Type 2 diabetes to slow the progression of established retinopathy [Grade A, Level 1].

Reference:

Altomare F, Kherani A, Lovshin J. Retinopathy. Canadian Journal of Diabetes. 2018;42:S210-S216. doi:10.1016/j.jcjd.2017.10.027
Categories
CDE Diabetes

Flashcards: Chronic Kidney Disease in Diabetes (Chapter 29 – 2025 Update)

The 2025 Guidelines Update marks a fundamental shift in practice—moving away from a glucocentric view toward a comprehensive strategy focused on delaying renal progression and reducing cardiovascular risk. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the updated diagnostic criteria, the new foundational role of SGLT2 inhibitors, and the specific indications for non-steroidal mineralocorticoid receptor antagonists (MRAs).

Key Topics Covered:

  • Diagnostic Criteria: Memorizing the thresholds for CKD diagnosis: an eGFR <60 mL/min/1.73 m² and/or a random Urine Albumin-to-Creatinine Ratio (UACR) 2.0 mg/mmol on repeated measures.

  • Foundational Therapy: Understanding the recommendation to use SGLT2 inhibitors as a primary treatment for renoprotection in eligible patients, regardless of glycemic control.

  • New Agents: Identifying finerenone (a non-steroidal MRA) as an add-on therapy for patients with Type 2 diabetes and CKD who remain at risk despite standard care.

  • RAAS Blockade: Recalling the rule to use an ACE inhibitor or an ARB for albuminuric patients, but never to combine them due to hyperkalemia and acute kidney injury risk.

  • Sick Day Management: Reviewing the “SADMANS” protocol for holding medications during acute illness to prevent acute kidney injury.

Categories
CDE Diabetes

Practice Exam: Chronic Kidney Disease in Diabetes (Chapter 29 – 2025 Update)

Diabetes remains the leading cause of kidney failure in Canada. The 2025 Guidelines Update represents a significant evolution in care, moving beyond simple glucose control to a “kidney-protective” strategy that utilizes newer pharmacotherapies to delay progression and reduce cardiovascular risk.

This practice exam tests your ability to apply the latest screening protocols, diagnostic criteria, and the expanded treatment algorithms for patients with varying stages of renal impairment.

Key Concepts Covered in This Exam:

  • Screening & Diagnosis: Mastering the criteria for diagnosing Chronic Kidney Disease (CKD) using the Urine Albumin-to-Creatinine Ratio (UACR) and eGFR, and distinguishing persistent albuminuria from transient causes.

  • Renoprotective Pharmacotherapy: Applying the updated recommendations for SGLT2 inhibitors as a foundational treatment for delaying CKD progression, even in patients without optimal glycemic control.

  • Non-Steroidal MRAs: Identifying the specific indications for finerenone (a non-steroidal mineralocorticoid receptor antagonist) in patients with Type 2 diabetes and CKD who remain at risk despite standard-of-care treatment.

  • RAAS Blockade: Reviewing the use of ACE inhibitors or ARBs for albuminuric patients and the critical caution against using them in combination.

  • “Sick Day” Management: Recognizing when to temporarily pause medications (like SADMANS) to prevent acute kidney injury during intercurrent illness.

Please go to Practice Exam: Chronic Kidney Disease in Diabetes (Chapter 29 – 2025 Update) to view this quiz

Categories
CDE Diabetes

Study Guide: Chronic Kidney Disease in Diabetes (2025 Update – Chapter 29)

1. Overview & Diagnosis

Chronic Kidney Disease (CKD) is a frequent complication of diabetes, affecting ~50% of people with Type 2 diabetes and 30% of those with Type 1 diabetes. It is a major driver of cardiovascular (CV) mortality.

  • Definition of CKD:

    • eGFR:

    • AND/OR

    • Albuminuria: Urine Albumin-to-Creatinine Ratio (ACR)

    • Duration: Abnormalities must persist for > 3 months.

  • Screening Frequency:

    • Type 1 Diabetes: Start screening 5 years after diagnosis, then annually.

    • Type 2 Diabetes: Start screening at diagnosis, then annually.

    • Method: Random urine ACR + Serum Creatinine (to calculate eGFR).

  • Diagnosis Confirmation:

    • A single abnormal ACR is not sufficient. It must be confirmed with 2 out of 3 tests being abnormal over a 3-month period.

    • False Positives: Exercise, infection, fever, congestive heart failure, menstruation, and acute hyperglycemia can transiently elevate ACR.

2. Comprehensive Management (The "Pillars")

The 2025 guidelines emphasize a multi-pillar approach to delay progression and reduce CV risk.

A. Glycemic & Blood Pressure Control

  • A1C Target: Individualized (usually ).

  • Blood Pressure: Target .

B. Pharmacotherapy: The 4 Classes

  1. ACE Inhibitors (ACEi) or ARBs (RAAS Blockade):

    • Indication: Recommended for people with diabetes, hypertension, and albuminuria (ACR ).

    • Caution: Monitor creatinine and potassium. A rise in creatinine of up to 30% is acceptable upon initiation; do not stop unless it exceeds this. Do not combine ACEi and ARB.

  2. SGLT2 Inhibitors (Flozins):

    • Indication: Strongly recommended for adults with Type 2 Diabetes and CKD (eGFR ) to reduce CKD progression and heart failure.

    • Effect: Reduces intraglomerular pressure.

    • Initiation: Can be started if eGFR and continued until dialysis is required.

  3. Mineralocorticoid Receptor Antagonists (MRA) – Finerenone:

    • Indication: For adults with Type 2 Diabetes and CKD (eGFR ) who have persistent albuminuria despite maximizing ACEi/ARB and SGLT2i.

    • Type: Finerenone is a non-steroidal MRA (unlike spironolactone) and has less risk of side effects but still requires potassium monitoring.

  4. GLP-1 Receptor Agonists:

    • Role: Recommended for CV risk reduction in T2D and CKD. Can be used if SGLT2i is contraindicated or not tolerated.

    • Note: Dose adjustment may be needed for renal function depending on the specific agent.

3. Acute Kidney Injury (AKI) & Sick Days

Educating patients on preventing AKI during intercurrent illness is a core CDE competency.

  • SADMANS Rule: Patients should temporarily stop the following medications when sick (vomiting, diarrhea, unable to hydrate):

    • S = Sulfonylureas

    • A = ACE Inhibitors

    • D = Diuretics / Direct Renin Inhibitors

    • M = Metformin

    • A = ARBs

    • N = NSAIDs

    • S = SGLT2 Inhibitors

4. Management of Hyperkalemia

Hyperkalemia is a barrier to using life-saving drugs (RAAS inhibitors, MRAs).

  • Diet: First-line management is dietary restriction of potassium.

  • Binders: If hyperkalemia persists, consider Potassium Binders (Patiromer or Sodium Zirconium Cyclosilicate) to allow continuation of RAAS blockade rather than stopping the medication.

5. Referral to Nephrology

Referral is indicated if:

  • Progressive Loss: Rapid decline in eGFR ().

  • Advanced Disease: eGFR .

  • Uncertainty: Etiology of kidney disease is unknown.

  • Management Issues: Unable to control BP or hyperkalemia.

6. 2025 Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section.

  1. Screening: Screen annually with random urine ACR and eGFR [Grade D, Consensus].

  2. SGLT2 Inhibitors: Recommended for patients with T2D and CKD (eGFR ) to reduce progression of kidney disease and CV events [Grade A, Level 1A].

  3. Finerenone: Recommended for patients with T2D and CKD (ACR > 3.0 mg/mmol) with normal potassium, to reduce progression of CKD and CV events [Grade A, Level 1A].

  4. RAAS Blockade: ACEi or ARB should be used in patients with diabetes, hypertension, and clinical albuminuria [Grade A, Level 1].

  5. Hyperkalemia: In patients with hyperkalemia limiting the use of RAAS inhibitors/MRAs, use potassium binders (Patiromer or SZC) to enable continuation of therapy [Grade B, Level 2].

Reference:

Tobe SW, Bajaj HS, Tangri N, et al. Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline. Canadian Journal of Diabetes. 2025;49(2):73-86.e14. doi:10.1016/j.jcjd.2025.01.004
Categories
CDE Diabetes

Flashcards: Treatment of Diabetes in People with Heart Failure (Chapter 28)

Heart failure is a frequent and often fatal complication of diabetes. The 2018 Clinical Practice Guidelines mark a major shift in treatment, prioritizing agents that specifically reduce heart failure hospitalizations and identifying those that may cause harm. These flashcards are designed to help pharmacists and healthcare professionals memorize the safety profiles and outcome data for SGLT2 inhibitors, TZDs, and DPP-4 inhibitors in this high-risk population.

Key Topics Covered:

  • Therapeutic Benefit: Identifying the specific role of SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) in reducing the risk of heart failure hospitalization in patients with established cardiovascular disease.

  • Agents to Avoid: Recognizing the risk of fluid retention and heart failure exacerbation associated with Thiazolidinediones (TZDs).

  • Safety Signals: Recalling the specific concern regarding saxagliptin and increased heart failure hospitalization rates seen in the SAVOR-TIMI 53 trial.

  • Epidemiology: Understanding that diabetes is an independent risk factor for heart failure (“diabetic cardiomyopathy”) and significantly worsens prognosis.

  • Neutral Agents: Knowing which drug classes (e.g., most GLP-1 receptor agonists) are considered safe/neutral regarding heart failure outcomes .

Categories
CDE Diabetes

Practice Exam: Treatment of Diabetes in People with Heart Failure (Chapter 28)

Heart failure is one of the most common and serious cardiovascular complications of diabetes, with up to 40% of people with heart failure having comorbid diabetes. The 2018 Clinical Practice Guidelines mark a significant paradigm shift, prioritizing the use of specific glucose-lowering agents that have been proven to reduce heart failure hospitalizations, while identifying others that may cause harm.

This practice exam tests your ability to navigate these critical therapeutic choices, ensuring you can select the safest and most effective regimens for this vulnerable patient population.

Key Concepts Covered in This Exam:

  • The SGLT2 Inhibitor Benefit: Understanding the recommendation to use SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) in patients with clinical cardiovascular disease to specifically reduce the risk of heart failure hospitalization.

  • Agents to Avoid: Identifying Thiazolidinediones (TZDs) as agents that cause fluid retention and are associated with an increased risk of heart failure.

  • DPP-4 Inhibitor Caution: Recognizing the specific safety signal associated with saxagliptin, which was shown to increase the rate of hospitalization for heart failure in the SAVOR-TIMI 53 trial.

  • Epidemiology and Risk: Acknowledging that heart failure is a major driver of mortality in diabetes and that the presence of diabetes significantly worsens the prognosis for patients with established heart failure.

  • Neutral Agents: Knowing which other antihyperglycemic agents (such as most GLP-1 receptor agonists) have demonstrated safety—but not necessarily benefit—regarding heart failure outcomes.

Please go to Practice Exam: Treatment of Diabetes in People with Heart Failure (Chapter 28) to view this quiz